Jim Simons
AKTS

Jim Simons’s Aktis Oncology AKTS Stock Holding History

Jim Simons’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.07M Buy
+95,400
New +$1.96M ﹤0.01% 1728

Other funds holding AKTS

BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jim Simons's AKTS Position: Q2 2026 in Review

Jim Simons opened a new position in Aktis Oncology (AKTS) in Q2 2026: 95,400 shares worth $3.07M. The stake represents ﹤0.01% of the portfolio and ranks #1728 among its holdings.

68 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Jim Simons held 95,400 shares of Aktis Oncology worth $3.07M as of Q2 2026.
  • Aktis Oncology was a new Jim Simons position in Q2 2026.
  • Aktis Oncology made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #1728 holding.
  • 68 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.